- Nano cap Trovagene (TROV) is up 16% premarket on light volume in reaction to updated results from its ongoing open-label Phase 1b/2 clinical trial evaluating onvansertib, combined with standard-of-care chemo, in patients with acute myeloid leukemia (AML).
- The company says the best results have been observed in the onvansertib + decitabine arm where 50% (n=3/6) of evaluable patients receiving the two highest doses to date achieved complete responses.
- According to ClinicalTrials.gov, the estimated primary completion date is January 2020.